Lavorato 2012.
| Methods | Two‐arm parallel RCT | |
| Participants | 32 infertile women undergoing ICSI cycle Inclusion criteria: women aged 37 years or less and in their first IVF/ICSI cycle, BMI < 30 kg/m2, regular menses and the presence of two normal ovaries Baseline characteristics: age (years) antagonist: 32.1 ± 3.1; agonist: 33.7 ± 2.7, P = 0.12; BMI: GnRH antagonist 23.4 ± 2.7, GnRH agonist 23.7 ± 3.1, P = 0.75 |
|
| Interventions |
GnRH antagonist (n = 16): on the third day of the menstrual cycle, ovarian stimulation was started with a fixed dose of 150 – 225 IU rFSH and 75 IU/day rLH for five days. On the eighth day of the menstrual cycle (sixth day of ovarian stimulation), follicular development was monitored by transvaginal ultrasound. The dose of rFSH was adapted according to the ovarian response, and supplementation with rLH was increased to 150 IU/day when one or more follicles measuring 10 mm in diameter were found. The GnRH antagonist, at a dose of 0.25 mg/day SC was started when at least one follicle greater or equal to 14 mm was observed on ultrasound GnRH agonist (n = 16) First, pituitary down‐regulation was started during the luteal phase of the previous menstrual cycle with the GnRH agonist at a dose of 1 mg/day for 14 days. Then, ovarian stimulation was started with a fixed dose of 150–225 IU recombinant FSH (rFSH/Gonal F1; Serono, SP, Brazil) with 75 IU/day rLH (Luveris1; Serono, SP, Brazil) for seven days. On the eighth day of ovarian stimulation, follicular development was monitored by transvaginal ultrasound. The dose of rFSH was adapted according to the ovarian response, and rLH supplementation was increased to 150 IU/day when one or more follicles measuring greater than or equal to 10 mm in diameter were found Additional support: for both groups, 250 mg r‐hCG (Ovidrel1; Serono, SP, Brazil) was administered SC when at least two follicles reached a diameter of 17 mm during final oocyte maturation. Oocyte retrieval was performed by transvaginal aspiration under ultrasound guidance 34 – 36 h after r‐hCG injection |
|
| Outcomes | None of the reported outcomes (DNA fragmentation, apoptosis) were relevant to the review | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Computer‐generated random sequence |
| Allocation concealment (selection bias) | Unclear risk | The method used in allocation concealment was not reported |
| Blinding (performance bias and detection bias) All outcomes | Unclear risk | No information was reported on blinding of participants and personnel, including outcome assessors. However, none of the reported outcomes were relevant to the review |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | None of the reported outcomes were relevant to the review |
| Selective reporting (reporting bias) | Unclear risk | None of the reported outcomes were relevant to the review |
| Other bias | Low risk | Groups were balanced at baseline |